Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2017 16:10 ET | Source: Aileron Therapeutics

Aileron Therapeutics Reports Second Quarter 2017 Financial Results

Initial clinical data showing anti-tumor activity with ALRN-6924 presented at ASCO 2017 -Presentation selected for Best of ASCO Meetings Ongoing enrollment of clinical trials in PTCL and AML/MDS ...
August 03, 2017 07:00 ET | Source: Aileron Therapeutics

Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today...
June 28, 2017 22:06 ET | Source: Aileron Therapeutics

Aileron Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for...
November 18, 2013 06:00 ET | Source: Rein Therapeutics

Aileron Therapeutics Secures $30 Million in New Financing

Company to Advance Pipeline of Clinical Candidates Based on its Innovative Stapled Peptide Platform Funding Accelerates Lead Oncology Program, ALRN-6924, a First-in-Class Dual Inhibitor of...